海尔生物
(688139)
| 流通市值：110.14亿 | | | 总市值：110.14亿 |
| 流通股本：3.18亿 | | | 总股本：3.18亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,761,188,311.04 | 1,195,500,051.78 | 688,989,400.7 | 2,283,832,911.43 |
| 营业收入 | 1,761,188,311.04 | 1,195,500,051.78 | 688,989,400.7 | 2,283,832,911.43 |
| 二、营业总成本 | 1,585,741,477.6 | 1,066,058,361.3 | 575,353,290.72 | 1,941,857,521.47 |
| 营业成本 | 942,056,612.63 | 642,201,576.13 | 355,833,943.97 | 1,187,914,554.76 |
| 税金及附加 | 17,541,367.95 | 11,302,560.43 | 7,029,318.27 | 23,293,190.71 |
| 销售费用 | 261,326,293.36 | 173,897,821.56 | 90,073,206.11 | 290,373,566.16 |
| 管理费用 | 144,351,857.08 | 95,964,069.93 | 47,989,485.05 | 181,359,437.04 |
| 研发费用 | 242,638,381.62 | 160,107,590.16 | 80,452,189.16 | 306,171,076.92 |
| 财务费用 | -22,173,035.04 | -17,415,256.91 | -6,024,851.84 | -47,254,304.12 |
| 其中:利息费用 | 2,870,080.47 | 1,916,197.01 | 976,876.36 | 3,410,319.59 |
| 其中:利息收入 | 25,163,808.59 | 16,054,023.05 | 8,771,449.17 | 47,662,107.06 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,021,962.32 | 1,894,977.61 | 219,653.28 | 5,468,787.54 |
| 加:投资收益 | 21,375,762.75 | 15,907,644.87 | 7,530,986.84 | 23,794,761.37 |
| 资产处置收益 | 186,508.98 | -18,792.77 | -38,090.35 | 233,571.76 |
| 资产减值损失(新) | -3,749,191.32 | -2,932,521.61 | -820,178.91 | -2,756,186.74 |
| 信用减值损失(新) | -14,374,998.15 | -11,508,828.9 | -7,133,412.84 | -15,535,293.57 |
| 其他收益 | 30,932,247.14 | 24,753,524.61 | 13,151,143.91 | 48,646,778.42 |
| 四、营业利润 | 211,839,125.16 | 157,537,694.29 | 126,546,211.91 | 401,827,808.74 |
| 加:营业外收入 | 975,898.12 | 390,737.12 | 121,649.36 | 3,247,061.03 |
| 减:营业外支出 | 2,630,049.89 | 1,735,387.71 | 1,177,982.82 | 3,118,165.04 |
| 五、利润总额 | 210,184,973.39 | 156,193,043.7 | 125,489,878.45 | 401,956,704.73 |
| 减:所得税费用 | 8,045,481.34 | 8,980,002.3 | 9,291,909.26 | 20,948,658.93 |
| 六、净利润 | 202,139,492.05 | 147,213,041.4 | 116,197,969.19 | 381,008,045.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 202,139,492.05 | 147,213,041.4 | 116,197,969.19 | 381,008,045.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 198,390,896.36 | 142,739,180.8 | 110,258,240.35 | 366,632,797.05 |
| 少数股东损益 | 3,748,595.69 | 4,473,860.6 | 5,939,728.84 | 14,375,248.75 |
| 扣除非经常损益后的净利润 | 173,473,083.52 | 123,484,524.2 | 99,168,300.25 | 321,803,539.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.63 | 0.45 | 0.35 | 1.16 |
| (二)稀释每股收益 | 0.63 | 0.45 | 0.35 | 1.16 |
| 八、其他综合收益 | 297,407.11 | 625,201.66 | 457,278.77 | -13,065,819.88 |
| 归属于母公司股东的其他综合收益 | 297,407.11 | 625,201.66 | 457,278.77 | -13,065,819.88 |
| 九、综合收益总额 | 202,436,899.16 | 147,838,243.06 | 116,655,247.96 | 367,942,225.92 |
| 归属于母公司股东的综合收益总额 | 198,688,303.47 | 143,364,382.46 | 110,715,519.12 | 353,566,977.17 |
| 归属于少数股东的综合收益总额 | 3,748,595.69 | 4,473,860.6 | 5,939,728.84 | 14,375,248.75 |
| 公告日期 | 2025-10-31 | 2025-08-27 | 2025-04-30 | 2025-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |